Optimisation of CD70-targeted adoptive cell therapy Ghent University
The efficacy of CD19-directed chimeric antigen receptor (CAR-)T-cell therapy in different hematologic malignancies has put cell therapy as a novel treatment option on the map. While response rates are high, relapses due to antigen escape mutants or antigen downregulation and exhaustion of T-cells occur. In addition, finding optimal target antigens, especially for solid tumours has been proven difficult. In this project, we aim to optimize the ...